Profound Medical Corp. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
PROF Nasdaq 3840 www.profoundmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Profound Medical Corp.

Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - May 18th, 2026 7:55 am
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - May 15th, 2026 4:30 am
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - May 14th, 2026 5:00 am
Profound Medical Annual General and Special Meeting of Shareholders Voting Results - May 13th, 2026 6:41 pm
Profound Medical Q1 Earnings Call Highlights - May 8th, 2026 3:07 pm
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 3:55 pm
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates - May 7th, 2026 2:41 pm
Profound Medical Reports Strong First Quarter 2026 Financial Results - May 7th, 2026 2:05 pm
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future - May 3rd, 2026 6:04 am
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates - Apr 30th, 2026 6:30 am
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference - Apr 25th, 2026 2:02 pm
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow - Apr 16th, 2026 6:37 am
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - Apr 14th, 2026 5:30 am
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting - Apr 1st, 2026 6:15 am
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone - Mar 27th, 2026 5:45 am
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Mar 26th, 2026 7:25 am
Profound Medical reports CAPTAIN trial meets primary safety endpoint - Mar 14th, 2026 8:40 am
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence - Mar 13th, 2026 8:30 am
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24 - Mar 9th, 2026 6:30 am
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Mar 5th, 2026 10:02 pm